How to Win an MM&M Award: 2015

You have fewer than six weeks to enter the MM&M Awards. No problem. Follow our checklist of Do's and Don'ts and tune in to our ...

Mobile Marketing: It's Go Time

The sales reps are game, the HCPs are receptive and the mobile technology is ready. Rebecca Mayer Knutsen reports on the circumstances that have converged ...

Formulary Fireworks

In the wake of the high-profile showdown between Gilead and Express Scripts over the pricing of hepatitis-C drugs Sovaldi and Harvoni, the pharma/PBM balance of ...

Journal Ad Review: Back in the Mix

A few years ago medical publishers were approaching a cliff and the choices were simple: Evolve the business or fall over the edge. By having ...

Headliner: New Synta chief adds commercialization clout

Anne Whitaker, President and CEO, Synta Pharmaceuticals

Therapeutic Focus: Metabolic

Is this finally the year that anti-obesity drugs make the leap from niche curio to mainstream therapy? Frank Celia reports on the changing practitioner mind-set ...

Latest

Consumers: Patients and Virtues

Consumers: Patients and Virtues

Consumers come with the same basic set of instructions as HCPs—find out what they need, then offer meaningful solutions. But be warned: Shiny objects may cause a temporary loss of vision

Healthcare Professionals: Chaos Breeds Opportunity

Increasingly pressed for time, the last thing physicians need is more engagement opportunities with pharma, right? Wrong. It's all about offering the right content in the right format at the right time

Overview: Can't, Won't, Don't Stop

Overview: Can't, Won't, Don't Stop

As pharma continues to scale the digital curve, James Chase's assessment of the landscape paints a familiar picture of progress and encouragement mixed with frustration and pain

Five things for pharma marketers to know: Tuesday March 3

Five things for pharma marketers to know: Tuesday March 3

NICE greenlights Harvoni for Britain's national formulary, Pacira received a CRL instead of an expanded indication and Novo's latest diabetes outreach focuses on patients instead of drug brands.

Amgen results for Kyprolis could sideline Velcade

Amgen results for Kyprolis could sideline Velcade

Analysts say head-to-head study results could make Kyprolis the lead treatment.

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

Oncologist's petition is latest salvo, as drug-pricing issue rises to new prominence

Drugmakers face increasing pressure on pricing from insurers and PBMs.

Pradaxa antidote goes to FDA

The breakthrough designation therapy drug was the first for its drug class.

GAO: Dementia patients receiving harmful antipsychotics

Researchers said 33% of Medicare Part D nursing home patients were receiving the drug for symptoms associated with dementia.

Five things for pharma marketers to know: Monday, March 2

Five things for pharma marketers to know: Monday, March 2

Boston Scientific buys Endo men's health business; Ranbaxy generic Nexium and Valcyte approvals denied by courts; BMS receives priority review for Opdivo lung-cancer indication.

Skill Sets: Cello Health Insight

Skill Sets: Cello Health Insight

A monthly showcase of companies offering expertise, experience and services within specific areas of the industry. In this edition: multichannel marketing

Agency Spotlight


 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters